Wegovy Tab: What the Oral Semaglutide Tablet Means for You

What the tablet actually is, and what makes it different from the jab

Semaglutide has been available as a once-weekly injection under the Wegovy brand for some time. The oral version uses a co-formulation technology: each tablet pairs semaglutide with a molecule called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), which protects the drug from stomach acid and allows it to be absorbed through the stomach lining. Without that co-formulation, semaglutide would simply be broken down before it reached the bloodstream. It is the same active ingredient doing the same thing (acting on GLP-1 receptors involved in appetite regulation and satiety) but the route in is completely different.

The clinical evidence behind it comes from OASIS 4, a phase-3 trial of 307 adults with obesity or overweight and at least one weight-related condition. Over 64 weeks, alongside lifestyle changes, participants taking the tablet lost an average of around 13.6% of their body weight compared with around 2.4% on placebo. Among those who adhered fully to treatment the figure reached approximately 17%, though that result applies specifically to the fully adherent group rather than the trial population as a whole. The MHRA's approval, which made the UK the first country in Europe to license oral semaglutide for weight management, was based on this evidence. You can read the background on the NHS semaglutide medicines page for an accessible overview.

For anyone who has been looking at the injectable Wegovy pen and wondering whether a tablet might be a simpler option, that instinct is understandable. The two routes have different practical demands, which is precisely why the decision matters.

The morning routine the tablet asks of you

This is the factor that catches people out most often, and it is worth being honest about. The Wegovy tablet, unlike a straightforward take-with-breakfast medicine, has to be the very first thing you do: before coffee, before water beyond a small sip (up to around 120 ml of plain water only), before any other oral medicine, and certainly before food. You then wait at least 30 minutes before eating or drinking anything else. That window is not a rough guide, absorption studies show that even a small amount of food or liquid during those 30 minutes can substantially reduce how much semaglutide gets into your bloodstream.

For people with a clear, quiet morning routine, this is manageable. For shift workers, parents of young children, or anyone whose mornings are unpredictable, it is genuinely worth pausing over. The injectable pen, by contrast, can be taken on any day of the week at a broadly consistent time, with no food-interaction window. There is no right answer here; it is a lifestyle fit question. Our clinical team discusses exactly these practicalities during consultations, you can read more about how that process works on our about page.

One storage difference is a straightforward advantage for the tablet: no refrigerator required. The injectable pens must be kept at 2–8°C until first use, which creates complications when travelling or if your fridge situation is unreliable. The tablet stores at room temperature, which removes that constraint entirely.

Who the tablet is licensed for (and what the prescriber weighs up

The MHRA licensed the Wegovy tablet for adults with a BMI of 30 or above, or a BMI between 27 and 29.9 where at least one weight-related condition is present) conditions such as high blood pressure, raised cholesterol, type 2 diabetes or obstructive sleep apnoea. That mirrors the eligibility framework for the injectable version. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance; your prescriber applies those adjustments based on your individual assessment.

The tablet is not available on the NHS at the time of writing. A NICE appraisal would be required before NHS commissioning could begin, and that process has not yet concluded. For now, it is a private prescription only. If you are weighing up what private treatment costs typically look like, the Wegovy cost page covers the market context honestly.

There are situations where the tablet is not appropriate, pregnancy, breastfeeding, or if you are trying to conceive. The medicine is not licensed for under-18s. Certain gastrointestinal conditions and a history of medullary thyroid carcinoma or MEN2 syndrome require careful prescriber discussion. People already established on the 2.4 mg weekly injection may, subject to clinical assessment, move directly to the 25 mg tablet rather than starting the dose ladder from the beginning; that decision sits with the prescriber. The semaglutide overview covers the broader clinical picture if you want more background on the active ingredient itself.

Side effects to be aware of before you decide

The OASIS 4 trial reported gastrointestinal side effects in around 74% of participants taking the tablet, compared with 42% on placebo. Nausea, vomiting, diarrhoea and constipation are the most common, particularly in the early weeks and after each dose increase. For most people they are mild to moderate and ease as the body adjusts, but they are not trivial and they are worth factoring into your thinking. The GI profile is broadly similar to the injectable semaglutide, though some people find one route easier to tolerate than the other, that varies between individuals.

Signs that need prompt medical attention include severe stomach pain that does not settle, particularly if it radiates to the back, which can indicate pancreatitis. The MHRA monitors this risk across all GLP-1 medicines. You can report any suspected side effect through the Yellow Card scheme, and you should always tell your prescriber about anything unexpected rather than managing it alone.

The practical question the tablet asks you to answer is not really «injection or tablet» in the abstract, it is «which version of this treatment fits my actual life well enough that I will use it consistently?» Consistency is where results come from. If you are still working through that question, a conversation with a prescriber is the clearest path to an answer. Check your eligibility with our clinical team when you feel ready.